Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Protein recognition using synthetic surface-targeted agents.

Rishi Jain1, Justin T Ernst, Olaf Kutzki

  • 1Department of Chemistry, Yale University, New Haven, CT, USA.

Molecular Diversity
|June 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Prone-Transpsoas Approach for Single-Position Lateral Corpectomy: A Case Series.

Brain sciences·2026
Same author

Evaluating the Use of Large Language Models in Improving the Readability of Online Patient Education Materials for Peripheral Nerve Surgery.

Healthcare (Basel, Switzerland)·2026
Same author

Glioma-intrinsic MAPK/ERK signaling promotes immunotherapy efficacy through T cell infiltration and interferon responses.

Nature communications·2026
Same author

Higher social vulnerability is associated with lower rates of peripheral nerve decompression surgery.

Clinical neurology and neurosurgery·2026
Same author

The Aging World of Spinal Deformity Surgery: Epidemiological Trends Over A 12-Year Period.

Spine·2026
Same author

Paraoxonase 2 as a target for aging-related diseases.

The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology·2026
Same journal

Synthesis of 9H-furo[2,3-f]chromenes using multicomponent reactions of euparin: investigation of biological activity.

Molecular diversity·2026
Same journal

Discovery of novel perillyl and myrtenyl nucleobase conjugates as dual anti-Alzheimer and antimicrobial agents.

Molecular diversity·2026
Same journal

Integrative network pharmacology and molecular modelling identify taxifolin as a potential modulator of melatonin receptor MT1 in mood disorders.

Molecular diversity·2026
Same journal

Design, synthesis and biological evaluations of novel VEGFR-2 inhibitors based on Fruquintinib and Cabozantinib.

Molecular diversity·2026
Same journal

Integrative subtractive genomics and molecular dynamics-based approach for drug repurposing against female genital tuberculosis.

Molecular diversity·2026
Same journal

Design, synthesis, and biological evaluation of novel isobenzofuran-1(3H)-one derivatives with antioxidant properties and improved oral bioavailability.

Molecular diversity·2026
See all related articles

Designing synthetic agents to block protein interactions is a novel approach. This review details strategies using protein structure mimetics to disrupt disease-related protein-protein interactions effectively.

Area of Science:

  • Medicinal Chemistry
  • Biochemistry
  • Drug Discovery

Background:

  • Protein-protein interactions (PPIs) are crucial in cellular processes.
  • Targeting PPIs offers therapeutic potential but faces challenges.
  • Recent years have seen limited focus on synthetic agents for PPI disruption.

Purpose of the Study:

  • To review strategies for designing synthetic agents that disrupt PPIs.
  • To explore the use of protein secondary and tertiary structure mimetics.
  • To highlight the potential of these agents in disease models.

Main Methods:

  • Reviewing existing literature on synthetic agent design for PPIs.
  • Analyzing strategies for targeting diverse protein surface types.
  • Examining the use of protein structure mimetics (e.g., peptides, small molecules).

Related Experiment Videos

Main Results:

  • Demonstrated success in achieving strong and selective binding to protein surfaces.
  • Successful disruption of clinically relevant PPIs in preclinical models.
  • Validation of structure-based design approaches for PPI inhibitors.

Conclusions:

  • Synthetic agents mimicking protein secondary or tertiary structures are effective PPI disruptors.
  • This approach holds promise for developing novel therapeutics against diseases driven by PPIs.
  • Further research into structure-based design can unlock new therapeutic avenues.